Invitation to Presentation of Egetis’ Fourth Quarter and Year-End 2024 Report on February 26, 2025

Stockholm, Sweden, February 21, 2025. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced that it will publish its fourth quarter 2024 report on Wednesday, February 26, 2025, at 07:00 am CET. Egetis will also host a conference call the same day at 10:00 am CET to discuss the fourth quarter 2024 financial results and give a corporate update.

If you wish to participate via webcast, please use the link below. You can ask written questions via the webcast.
https://egetis.events.inderes.com/q4-report-2024

If you wish to participate via teleconference, please register via the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/egetis/q4-report-2024/dial-in

The conference call will be made available on the Company’s website after the call.

About Egetis Therapeutics

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

On February 13, 2025, the European Commission approved Egetis’ Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency

The Company’s lead drug candidate tiratricol (Emcitate®) is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) tiratricol has shown highly significant and clinically relevant results on serum thyroid hormone T3 concentrations and secondary clinical endpoints. The Phase 2 study, Triac Trial II, investigated a treatment effect on neurocognitive development in young children under 30 months of age with MCT8 deficiency, and did not show a statistically significant improvement compared to historical controls.

After a dialogue with the FDA, Egetis is conducting a randomized, placebo-controlled pivotal study in at least 16 evaluable patients to verify the results on T3 levels seen in previous clinical trials and publications. As previously communicated, the Company will update the market as soon as recruitment closes, and at that time, the Company will also provide information on when to expect topline results and when the Company plans to submit the NDA application.

Tiratricol holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Tiratricol has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.

The drug candidate calmangafodipir (Aladote®) is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed. The design of a pivotal Phase 2b/3 study (Albatross), with the purpose of applying for market approval in the US and Europe, has been finalized following interactions with the FDA, EMA and MHRA. The development program for calmangafodipir has been parked until tiratricol marketing authorization submissions for MCT8 deficiency have been completed in the EU and the USA. Calmangafodipir has been granted ODD in the US and in the EU.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see www.egetis.com